Foundayo's $149 headline is a one-month starter price — the real cash-pay year runs $3,338–$3,738 once you escalate. Compare PlexusDx Microdose GLP-1 ($129/mo flat), Semaglutide Oral ($209+/mo), and Tirzepatide Oral ($229+/mo) on annualized cost.

Foundayo costs $25/month with covered commercial insurance, $50/month on the Medicare GLP-1 Bridge, or $149–$349/month self-pay through LillyDirect. Most commercial plans don't cover GLP-1s for weight loss in 2026. Compare cash-pay PlexusDx Weight Management Protocols — Microdose at $129/mo flat, Semaglutide Injection $179–$229/mo, Tirzepatide Injection $229–$309/mo — with no membership fee.

Eden semaglutide reviews reveal flat-dose pricing strengths, BBB complaint friction, and four published price points across Eden's own pages. Compare Eden's compounded semaglutide with PlexusDx Semaglutide Injection ($179–$229/mo), Microdose GLP-1 ($129/mo flat), and Semaglutide Oral (from $209/mo) — cash-pay, no membership, with optional genetic-test dose personalization.

Eden vs Ro vs PlexusDx for cash-pay GLP-1 weight loss in 2026: real annualized cost math on Eden’s $129–$329/mo all-inclusive compounded plans, Ro’s $149/mo membership plus FDA-approved branded medication (Wegovy, Zepbound, Ozempic, Foundayo), and PlexusDx Weight Management Protocols from $129/mo — with the Precision Peptide Genetic Test as a $99 add-on so dosing is anchored to GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants before week one.

Eden cancellation policy explained: $0 fee, no contract, but refunds hinge on the pharmacy cutoff. Step-by-step portal and email cancellation, prepaid 3-month plan rules, medical-reason refund path, and how PlexusDx month-to-month protocols ($129–$509/mo, no membership, all 50 states) sidestep the cutoff problem.

MEDVi’s compounded plans bundle medication and platform into one price (no separate membership fee); branded Wegovy/Zepbound paths add a $99/mo membership. We reconcile MEDVi’s fee structure, the 28-day billing cycle, and where PlexusDx Weight Management Protocols sit at $129–$325/mo with no membership fee on any tier.

Medicare Part D is statutorily prohibited from covering GLP-1s prescribed solely for weight loss, and manufacturer copay cards are off-limits to Medicare beneficiaries. This guide explains the Medicare GLP-1 Bridge launching July 2026, Part D backdoors for diabetes, CVD, and OSA, and the cash-pay options that work today — including PlexusDx Microdose GLP-1 Protocol at $129/mo flat and Semaglutide Injection at $179–$229/mo.

How PlexusDx Weight Management Protocols compare to the major cash-pay GLP-1 programs in 2026 — Mochi, Eden, MEDVi, Ro, GoodRx Care Direct, NovoCare, and LillyDirect — on price, medication source, membership fees, and total annualized cost.

503A vs 503B compounding pharmacy explained — the regulatory framework, FDA Modernization Act of 1997 and Drug Quality and Security Act of 2013, oversight differences, and a five-step verification checklist for compounded GLP-1 medications.

Are GLP-1 pills safe? Four are FDA-approved in 2026 (Rybelsus, Ozempic tablets, Wegovy tablet, Foundayo). Patient-specific compounded oral GLP-1s through licensed pharmacies are a separate lawful category. No-prescription drops and gummies aren't legitimate. Here's the safety framework, the boxed-warning context, and where PlexusDx oral protocols fit.

A buyer-side read of the seven brand-name GLP-1 telehealth providers (Ro, Walgreens, GoodRx, Hims & Hers, PlushCare, Sesame, WeightWatchers) covering true month-one cost, what each dispenses, and how PlexusDx compounded protocols ($129–$325/mo, all-inclusive, no membership) fit when branded coverage isn't accessible.

How to verify a 503A compounding pharmacy before ordering compounded semaglutide or tirzepatide: eight automatic walk-away triggers, a 10-minute audit using state-board, FDA, PCAB, and NABP databases, and where PlexusDx Weight Management Protocols sit in that framework.

Wegovy oral options as of April 2026: this article explains what formats are FDA-approved, how oral and injection forms compare on bioavailability and dosing, what administration requires, and the PlexusDx Weight Management Protocols that offer both oral and injection options.

Wegovy oral options as of April 2026: this article explains what formats are FDA-approved, how oral and injection forms compare on bioavailability and dosing, what administration requires, and the PlexusDx Weight Management Protocols that offer both oral and injection options.

Ozempic is a GLP-1 pathway compound relevant to weight management through its effects on appetite, satiety, and metabolism. This article covers mechanism, clinical trial evidence, FDA-approved indications, boxed-warning safety, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape every GLP-1 response.

Ozempic is a GLP-1 pathway compound relevant to weight management through its effects on appetite, satiety, and metabolism. This article covers mechanism, clinical trial evidence, FDA-approved indications, boxed-warning safety, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape every GLP-1 response.

Wegovy 25 mg is one step in the FDA-approved dose-titration schedule for this compound. This article reports what the label says about the 25 mg dose, common patient experiences at this step, when the next step typically happens, and the GLP-1 pathway genetics underneath every dose decision.

Wegovy 0.25 mg is one step in the FDA-approved dose-titration schedule for this compound. This article reports what the label says about the 0.25 mg dose, common patient experiences at this step, when the next step typically happens, and the GLP-1 pathway genetics underneath every dose decision.

Ozempic 2.0 mg is one step in the FDA-approved dose-titration schedule for this compound. This article reports what the label says about the 2.0 mg dose, common patient experiences at this step, when the next step typically happens, and the GLP-1 pathway genetics underneath every dose decision.

Wegovy list price is approximately $1,349 per month at U.S. list price as of April 2026 (Novo Nordisk published pricing). This article covers insurance coverage, manufacturer savings programs, compounded alternatives, and PlexusDx Weight Management Protocols as of April 2026.

Compounded Ozempic refers to formulations produced by licensed 503A compounding pharmacies — not the FDA-approved brand product. This article covers what 503A pharmacies can legally do, the FDA 2024–2025 shortage resolutions, how compounded products compare to brand products, common variations like B12 combinations, and PlexusDx Weight Management Protocols.

Compounded Ozempic refers to formulations produced by licensed 503A compounding pharmacies — not the FDA-approved brand product. This article covers what 503A pharmacies can legally do, the FDA 2024–2025 shortage resolutions, how compounded products compare to brand products, common variations like B12 combinations, and PlexusDx Weight Management Protocols.

Ozempic list price is approximately $968–$1,029 per month at U.S. list price as of April 2026 (Novo Nordisk published pricing). This article covers insurance coverage, manufacturer savings programs, compounded alternatives, and PlexusDx Weight Management Protocols as of April 2026.

Wegovy list price is approximately $1,349 per month at U.S. list price as of April 2026 (Novo Nordisk published pricing). This article covers insurance coverage, manufacturer savings programs, compounded alternatives, and PlexusDx Weight Management Protocols as of April 2026.

Wegovy overview: this article covers what it is, how it works mechanically, FDA-approved indications, common and serious side effects including the class boxed-warning context, April 2026 cost landscape, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape every GLP-1 response.

Ozempic list price is approximately $968–$1,029 per month at U.S. list price as of April 2026 (Novo Nordisk published pricing). This article covers insurance coverage, manufacturer savings programs, compounded alternatives, and PlexusDx Weight Management Protocols as of April 2026.

Wegovy is a GLP-1 pathway compound relevant to dietary support through its effects on appetite, satiety, and metabolism. This article covers mechanism, clinical trial evidence, FDA-approved indications, boxed-warning safety, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape every GLP-1 response.

Ozempic is a subcutaneous injection per the FDA-approved label, given in the abdomen, thigh, or upper arm with rotation within the chosen area. This article reports the label factually — including what to avoid, when to contact a provider, and how PlexusDx protocols include injection training.

Wegovy 2.4 mg is one step in the FDA-approved dose-titration schedule for this compound. This article reports what the label says about the 2.4 mg dose, common patient experiences at this step, when the next step typically happens, and the GLP-1 pathway genetics underneath every dose decision.

Ozempic overview: this article covers what it is, how it works mechanically, FDA-approved indications, common and serious side effects including the class boxed-warning context, April 2026 cost landscape, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape every GLP-1 response.